Anticholinergic Drug Burden in Persons with Dementia Taking a Cholinesterase Inhibitor: The Effect of Multiple Physicians
Authors:
Open Access
- 21 March 2016
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 64 (3) , 492-500
Abstract
Objectives: To explore the association between the number of physicians providing care and anticholinergic drug burden in older persons newly initiated on cholinesterase inhibitor therapy for the management of dementia. Design: Population‐based cross‐sectional study. Setting: Community and long‐term care, Ontario, Canada. Participants: Community‐dwelling (n = 79,067, mean age 81.0, 60.8% female) and long‐term care residing (n = 12,113, mean age 84.3, 67.2% female) older adults (≥66) newly dispensed cholinesterase inhibitor drug therapy. Measurements: Anticholinergic drug burden in the prior year measured using the Anticholinergic Risk Scale. Results: Community‐dwelling participants had seen an average of eight different physicians in the prior year. The odds of high anticholinergic drug burden (Anticholinergic Risk Scale score ≥ 2) were 24% higher for every five additional physicians providing care to individuals in the prior year (adjusted odds ratio = 1.24, 95% confidence interval = 1.21–1.26). Female sex, low‐income status, previous hospitalization, and higher comorbidity score were also associated with high anticholinergic drug burden. Long‐term care facility residents had seen an average of 10 different physicians in the prior year. After a sensitivity analysis, the association between high anticholinergic burden and number of physicians was no longer statistically significant in the long‐term care group. Conclusion: In older adults newly started on cholinesterase inhibitor drug therapy, greater number of physicians providing care was associated with higher anticholinergic drug burden scores. Given the potential risks of anticholinergic drug use, improved communication among physicians and an anticholinergic medication review before prescribing a new drug are important strategies to improve prescribing quality.Keywords
Funding Information
- Canadian Institutes of Health Research (OTG‐88591)
- Heart and Stroke Foundation of Canada
- University of Toronto
- Ontario Ministry of Health and Long-Term Care
This publication has 46 references indexed in Scilit:
- Electronic Prescribing and Other Forms of Technology to Reduce Inappropriate Medication Use and Polypharmacy in Older People: A Review of Current EvidenceClinics in Geriatric Medicine, 2012
- A merican G eriatrics S ociety Updated B eers C riteria for Potentially Inappropriate Medication Use in Older AdultsJournal of the American Geriatrics Society, 2012
- Care homes' use of medicines study: prevalence, causes and potential harm of medication errors in care homes for older peopleQuality and Safety in Health Care, 2009
- The cognitive impact of anticholinergics: A clinical reviewClinical Interventions in Aging, 2009
- Dual Use of Bladder Anticholinergics and Cholinesterase Inhibitors: Long‐Term Functional and Cognitive OutcomesJournal of the American Geriatrics Society, 2008
- Prescribing for older peopleBMJ, 2008
- A Population‐Based Study of Cholinesterase Inhibitor Use for DementiaJournal of the American Geriatrics Society, 2007
- Care Patterns in Medicare and Their Implications for Pay for PerformanceNew England Journal of Medicine, 2007
- Medication management at home: medication-related risk factors associated with poor health outcomesAge and Ageing, 2005
- Drug-Induced Cognitive Impairment in the ElderlyDrugs & Aging, 1999